New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.
The US Food and Drug Administration (FDA) has mandated that by 2023 medications have unit-level traceability through the Drug Supply Chain Security Act.
But how can this be achieved?
In a recent paper, researchers from Purdue University, US, revealed a technology that could meet this requirement.
Counterfeit medications and pharmaceutical products are just a click away from being purchased from online pharmacies via smartphone. However, the newly developed anti-counterfeiting technology could turn smartphones into lifesavers by allowing patients to simply take a picture of a cyber-physical watermark to confirm if a medication is real or not.
Purdue University biomedical engineers have developed new cyber-physical watermarks that allow people to check medication authenticity with a smartphone.
Young Kim, associate head for research and an associate professor in Purdue’s Weldon School of Biomedical Engineering, says the continued rise of counterfeit medications, pharmaceutical products and medical supplies can be attributed to the increase of online pharmacies, many of which are unregulated.
To counteract the issue, the FDA is requiring medications have unit-level traceability by 2023. But, while pharmaceutical companies currently have the ability to track boxes or sheets of medications, the jump to adding traceability directly to pills could require adding numerous manufacturing and data management steps, according to Kim.
Kim’s team proposes using small cyber-physical watermarks to trace medications and confirm whether they are real or fake, as well as allowing patients to confirm dose and frequency, and access additional information on the medicine.
People can use a smartphone app to activate a new cyberphysical watermark to detect whether the medication they are taking is real or fake. Purdue biomedical engineers have developed the cyberphysical watermark as a way to reduce fake medications.
“A paper watermark is commonly used on currency and a passport to discourage counterfeiting, and we are affixing a watermark on an individual medicine that is readable by a smartphone camera to extract a hidden digital key,” Kim said. “Purdue has an excellent track record of watermarking and inkjet printing research. We are proud that we have extended such national security research into pharmaceuticals as counterfeit medicines are a national security problem.”
The cyber-physical watermark is printed on specialised edible fluorescent silk with FDA-approved food dye using an inkjet printer. According to the researchers, using fluorescent silk is not only beneficial because it makes it difficult for counterfeiters to duplicate the watermark, but also because engineers can change the biopolymer’s shape, structure and flexibility. The engineers also addressed how to use the technology with different smartphone models, photo quality and light.
“A person can take a photo under different light conditions and will have different images. It is the same issue when patients take photos of our watermark in their phone,” Kim explained. “The reference colours on the watermark’s periphery allow us to know the true colour value of the watermarked image as each smartphone has different spectral sensitivity.”
Placed on pills using a simple sugar glue, the smallest size of watermark the team could produce is 5mm by 5mm. While the team has had success with solid pills, it is working also on developing technology for liquids.
Cyber-physical watermark technology could be used first on name-brand medications and restricted narcotics before being rolled out on over-the-counter medications and generics.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.
Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032
The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.
Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.